LifeSci Capital analyst Charles Zhu has maintained their bullish stance on TARA stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Zhu’s rating is based on several strategic developments and upcoming milestones for Protara Therapeutics. The company has announced the initiation of its Phase 3 THRIVE-3 trial by the end of 2025, which was delayed due to administrative and funding challenges. This trial is crucial for advancing TARA-002 in treating non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). Additionally, Protara is on track to release interim data for TARA-002 in both BCG-naive and BCG-unresponsive NMIBC patients, as well as in lymphatic malformations, by the end of 2025 and early 2026.
These data releases are expected to provide clarity on TARA-002’s efficacy, potentially positioning it as a competitive alternative to existing treatments like OK-432. Furthermore, the management has identified a significant patient population for TARA-002, highlighting its potential market impact. Despite the financial challenges, with a cash runway of approximately 1.6 years, the company’s strategic focus and upcoming data readouts underpin Charles Zhu’s Buy rating, reflecting confidence in Protara’s ability to achieve its clinical and regulatory objectives.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.